JNJ Stock Surges Past $240 on Strong Earnings Outlook and Bullish Analyst Upgrades

# Johnson & Johnson Stock Analysis: JNJ Surges 2% with Bullish Analyst Targets | March 2026 Market Update **Podcast Episode Description:** Dive into the latest Johnson & Johnson (JNJ) stock performance analysis as shares climb to $239.93 on March 25, 2026, marking a strong 1.98% gain. This comprehensive market update covers JNJ's impressive 2% intraday surge, bullish analyst upgrades from JP Morgan, HSBC, and Royal Bank of Canada, and upcoming Q1 2026 earnings expectations. **Episode Highlights:** - **Stock Performance:** JNJ reaches $241.46 high with detailed volume analysis - **Analyst Price Targets:** Upgraded targets ranging from $250-$280, consensus at $236.91 - **Earnings Preview:** April 14, 2026 earnings date with EPS forecast of $2.69 - **Valuation Metrics:** $577.9B market cap, 2.17% dividend yield, forward P/E of 20.39 - **Growth Forecast:** LongForecast projects $272 by April month-end - **Zacks Investment Rating:** #2 Buy rating based on positive earnings revisions Perfect for investors tracking pharmaceutical stocks, dividend income opportunities, and large-cap healthcare investments. Get expert insights on JNJ's market position, institutional analyst sentiment, and technical trading patterns. **Keywords:** Johnson & Johnson stock, JNJ stock analysis, healthcare stocks 2026, dividend stocks, pharmaceutical investments, earnings preview, analyst upgrades, market cap stocks *A Quiet Please Studios production - Subscribe for daily market insights and stock analysis* For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.